Please assess the completion status of the following clinical trial:

Trial Title: Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Transfusion Dependent Thalassemia~* If iron between 5-15 mg/g dry liver by SQUID, subject must have a documented endocrinopathy or cardiac finding~* Older than 8 years~Exclusion Criteria:~* Participating on another interventional clinical trial

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Exjade) and Deferoxamine (DFO) (Type: EXPERIMENTAL): All subjects received Deferasirox (Exjade) and Deferoxamine (DFO) dosing based on the iron overload at baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).